A growing body of scientific research increasingly suggests that aging may be far more flexible than once believed, opening new doors in the field of biogerontology. Now, researchers at Yale University have taken a critical, data-driven step forward in the quest to untangle the complex landscape of longevity science. By systematically evaluating a broad spectrum of interventions, the Yale team has moved closer to identifying which treatments can genuinely influence biological aging and which popular remedies show little to no measurable benefit.
The findings, recently published in the prestigious journal Nature Medicine, offer a clearer lens through which scientists can evaluate anti-aging therapies. According to the study, certain prescription medications and targeted lifestyle changes are consistently associated with a reduction in biological age as measured by sophisticated DNA-based blood tests. However, popular over-the-counter supplements that are widely marketed for longevity generally failed to produce the same encouraging effects in the data analyzed by the researchers.
While these discoveries provide a valuable new framework for the scientific community, the researchers emphasize an important caveat: reductions in biological age markers do not automatically guarantee that individuals will live longer lives or successfully evade age-related diseases. The ultimate connection between biomarker shifts and actual health outcomes remains a central question that ongoing research must address.
From Fighting Cancer to Understanding Aging
The roots of this comprehensive study trace back several years to when Raghav Sehgal first began his graduate studies at Yale. Initially, his academic trajectory and professional background pointed toward oncology. Armed with an undergraduate foundation in engineering and practical experience launching a computational biology startup, Sehgal intended to apply advanced computer science techniques to investigate cancer.
However, a pivotal conversation with his Ph.D. adviser at the Yale School of Medicine redirected his scientific curiosity entirely. Rather than focusing exclusively on isolated pathologies such as cancer or cardiovascular disease, his adviser posed a broader, foundational question: why not investigate the underlying aging process itself, which acts as a primary catalyst for the development of so many age-related illnesses?
"That put me on a different path," recalled Sehgal, who now serves as an associate research scientist in psychiatry with a specialization in computational biology and bioinformatics. "As researchers, we have a long way to go in understanding the aging process and whether the steps we take to manage it really work."
Today, Sehgal dedicates his research to uncovering the biological mechanisms driving human aging, refining the methods scientists use to measure those changes, and exploring why advancing age dramatically increases the vulnerability to conditions like cancer, diabetes, and dementia. Furthermore, his work investigates whether specific interventions might successfully reverse certain aspects of biological aging, even if completely halting or eliminating the aging process itself remains well beyond our current technological reach.
New DNA Tests Reveal Which Anti-Aging Treatments Work
Sehgal is the lead author of the newly published study, which was conducted within the laboratory of Albert Higgins-Chen, an assistant professor of psychiatry at the Yale School of Medicine. The research team set out to tackle a persistent challenge in biogerontology: determining which existing approaches to slowing aging produce physiological changes that can be reliably and objectively measured.
Through their meticulous analysis, the team uncovered encouraging results pointing toward specific medical therapies and lifestyle interventions. Conversely, the various over-the-counter supplements included in the broad review generally failed to demonstrate meaningful reductions in biological age markers.
The ambitious project was a collaborative effort involving members of the entire Higgins-Chen laboratory, including researchers Daniel Borrus, Jenel F. Armstrong, John Gonzalez, Jessica Kasamoto, and Yaroslav Markov. Their combined expertise allowed the team to process and synthesize a massive amount of clinical data that had previously remained fragmented across different studies.
"For the first time we’ve shown that certain therapies have measurable impacts," Sehgal noted, highlighting the significance of the undertaking. "This wasn’t previously possible, because we didn’t have enough data to say these biomarkers are consistently responsive to these interventions."
In scientific research, biomarkers serve as vital tools that provide quantifiable information about dynamic processes occurring inside the living body. Within the specific context of aging research, these biomarkers help investigators estimate a person’s biological or functional age, which can often deviate significantly from their chronological age based on birth dates alone.
How Scientists Measure Biological Age
To rigorously investigate whether various treatments could successfully influence the aging trajectory, the Yale team relied primarily on advanced blood-based measurements known broadly as epigenetic clocks.
These sophisticated diagnostic tools are designed to analyze chemical patterns attached directly to human DNA, focusing particularly on methyl groups—basic chemical structures that function much like molecular tags or switches. Decades of prior research have established that these specific chemical markers undergo predictable shifts as individuals grow older. Certain lifestyle or medical interventions may have the capacity to reverse some of these age-associated patterns, and complex computer algorithms utilize those detected shifts to calculate an individual’s estimated biological age.
To build a robust dataset, the Yale researchers gathered and synthesized findings from 51 distinct clinical studies that had previously investigated a wide array of anti-aging strategies. These interventions ranged widely from dietary supplements and prescription pharmaceuticals to intensive lifestyle modifications and specialized medical procedures.
Across that extensive collection of studies, the research team examined more than 110 individual DNA methylation biomarkers, which included 16 major epigenetic clocks currently recognized in the scientific field. By carefully comparing biological measurements taken before and after the administration of these interventions, the investigators could systematically evaluate which approaches correlated with reductions in biological age.
"What we did was pretty unique," Sehgal explained. "We already know that certain things might prolong health span and lifespan. There is data from retrospective analysis as well as from animal models. We took all that knowledge along with the real-world clinical studies to identify which interventions in humans were slowing down aging across the board in these known biomarkers."
Which Anti-Aging Treatments Showed the Best Results?
To make sense of the vast collection of data, the researchers categorized the diverse interventions into four primary groups: prescription medications, lifestyle modifications, over-the-counter supplements, and medical procedures.
One of the most definitive and consistent findings emerged around the pillars of diet and exercise. The analysis showed that combining regular physical activity with a healthy eating plan consistently reduced epigenetic age. The dietary regimens evaluated in the research spanned several well-known nutritional approaches, including the Mediterranean diet, low-fat diets, and low-carb diets.
However, the most pronounced reductions in biological age markers were strongly associated with specific pharmaceutical treatments. These included established prescription drugs such as metformin and semaglutide—medications frequently prescribed to manage metabolic conditions, blood sugar levels, and body weight—as well as anti-TNF therapies designed to target a specific protein involved in the body’s inflammatory response.
For clarity, TNF, or tumor necrosis factor, is an immune-system protein that plays a key role in helping the body fight inflammation-related injury, but chronic inflammation driven by such pathways is frequently linked to accelerated aging and tissue decline.
In contrast, the results were notably less encouraging when the researchers evaluated over-the-counter supplements and certain medical procedures. Within the scope of the clinical studies examined, these popular commercial approaches did not yield measurable reductions in epigenetic age, suggesting that consumer enthusiasm for many longevity supplements currently outpaces scientific evidence.
Furthermore, the research team made a technical discovery regarding the diagnostic tools themselves: newer generations of biological age clocks generally performed better and provided clearer signals than older versions. Another notable observation was that human participants who were actively living with diagnosed diseases typically experienced larger, more pronounced shifts in their aging biomarkers following interventions compared to healthy participants.
Could DNA Blood Tests Transform Anti-Aging Research?
Looking toward the future, Sehgal stated that the immediate priority for the research team is to test these findings within larger and more demographically diverse populations. Expanding the scope of the research will help scientists determine how consistently different therapeutic treatments influence biological aging across individuals with varying health conditions, genetic backgrounds, and environments.
If successfully scaled, these improved blood tests could dramatically shorten the notoriously long timelines traditionally required to evaluate potential anti-aging therapies.
"If these new biomarkers are eventually validated to predict long-term health, scientists will be able to evaluate anti-aging therapies much faster," Sehgal added. "Instead of waiting decades for evidence from clinical trials, we’ll be able to see which interventions are effective and in which people in a few years or even months."
This capability could represent a watershed moment for aging research. Rather than relying entirely on epidemiological and clinical studies that must follow human participants for decades to observe mortality or disease incidence, scientists might eventually utilize validated biological age measurements as reliable surrogate endpoints to identify promising treatments much earlier in the pipeline.
Nevertheless, senior author Albert Higgins-Chen stressed that the scientific community must exercise caution and discipline when interpreting what changes in these aging biomarkers actually signify in a real-world medical context.
"ษฐWe have developed a rigorous, systematic approach to evaluating and comparing how biomarkers change across a wide variety of interventions, and that is a critical step in the right direction," Higgins-Chen said. "However, the true meaning of that change must be fully understood."
Important Questions About Slowing Aging Remain
Although the Yale team’s results offer a promising foundation, several major scientific questions remain unanswered before these biomarkers can be fully integrated into standard clinical practice.
For instance, researchers must still establish definitive proof regarding whether changes in biological age are directly and causally induced by a specific treatment, or if they are partially influenced by confounding factors that were not fully accounted for in the original clinical trials. Additionally, scientists need to gain a clearer understanding of the kinetics involved—specifically, how rapidly those biomarker changes occur, whether they persist over time after a treatment is discontinued, and what precise intracellular mechanisms drive them.
Most importantly, the scientific community has not yet definitively established whether lowering a person’s epigenetic age directly translates into meaningful, tangible improvements in long-term health, functional independence, or resistance to chronic disease.
"And most importantly—what does the change mean for our long-term risk of age-related disease and functional decline?" Higgins-Chen reiterated.
Further investigations aimed at answering these critical questions are already underway, with additional studies being led by laboratory members Daniel Borrus, Jenel F. Armstrong, and Grace Zou. The Higgins-Chen laboratory maintains broad academic affiliations across Yale University, including the Department of Pathology, the Computational Biology and Bioinformatics Program, and the Y-Age Yale Center for Research on Aging.
Ultimately, while these new insights provide a much clearer picture of which interventions hold genuine potential to influence biological aging, researchers emphasize that extensive work lies ahead. Confirming these findings through rigorous follow-up studies will be essential to determining whether reductions in biological age markers will ever ultimately translate into fewer age-related diseases, prolonged health spans, or extended human lives.